Home / Health / HIV Pill: Weekly Dose Could Replace Daily Meds
HIV Pill: Weekly Dose Could Replace Daily Meds
3 Aug
Summary
- A new weekly oral pill is as effective as daily HIV treatment.
- The experimental pill combines two long-acting antiretroviral medicines.
- Over 93% of patients in a trial maintained suppressed HIV viral loads.
A new once-weekly oral pill could transform daily HIV care for patients. Researchers have reported that this experimental therapy is as effective as leading daily HIV treatments.
The pill combines two long-acting antiretroviral drugs, islatravir and lenacapavir, working together to allow for weekly dosing. This innovation offers a potential solution for individuals struggling with the strict schedule of daily medication.
A study involving over 600 adults across 12 countries found the weekly pill maintained viral suppression in over 93% of participants after 48 weeks, matching the efficacy of daily regimens. No patients on the weekly pill experienced a viral load increase.
This advancement provides enhanced flexibility for patients, potentially reducing the burden and stigma associated with daily pill-taking, particularly for those with co-occurring health conditions. The clinical trial, funded by Gilead Sciences and Merck Sharp & Dohme, is continuing to evaluate the treatment's long-term safety and effectiveness over 96 weeks.
